Altamira Therapeutics ("Altamira" or the
"Company") (NASDAQ:CYTO), a company dedicated to developing
therapeutics that address important unmet medical needs, today
announced the publication of a peer-reviewed article in the
scientific journal International Journal of Oral
Science titled, "Histone demethylase JMJD3 downregulation
protects against aberrant force-induced osteoarthritis through
epigenetic control of NR4A1" that covers an independently funded
study evaluating novel treatment approaches for osteoarthritis (OA)
conducted by a Shanghai-based research group.
Study highlights
The study used different approaches to downregulate the Jumonji
domain-containing protein D3 (JMJD3) gene to assess whether this
strategy would be beneficial for the treatment of OA. Nanoparticles
comprising a siRNA targeting the JMJD3 gene, and Altamira’s
peptide-based OligoPhore delivery platform (also known as “p5RHH”),
were used to locally downregulate the expression of JMJD3 in a
mouse model of OA. The study authors observed that, “the severity
of joint degeneration was remarkably mitigated” thanks to
administration of the nanoparticles and highlighted their
“advantage of specifically targeting inflammation in the joint
without off-target toxicities.” They propose JMJD3 inhibition –
based on the OligoPhore platform – as an “innovative epigenetic
therapy approach for joint diseases.”
In their study, the authors pursued an epigenetic-based
therapeutic approach (i.e. targeting gene regulation) to mitigate
cartilage inflammation and damage in a murine model of
osteoarthritis. OligoPhore was used to formulate siRNA polyplexes
that inhibited chondrocyte production of a histone demethylase,
JMJD3, in response to joint damage. JMJD3 is upregulated in joint
injury and drives other inflammatory pathways to elicit further
damage and chondrocyte programmed cell death. Injection of 2 weekly
doses of OligoPhore-siRNA into the affected joint over 8 weeks
significantly attenuated inflammation and preserved cartilage
viability and integrity.
CSO comments
"The study's results confirm prior findings reporting the
benefit of RNA therapeutics based on our nanoparticle delivery
platform in models in rheumatoid arthritis and, now,
osteoarthritis," commented Samuel Wickline, MD, Altamira
Therapeutics’ Chief Scientific Officer." One of the key features of
OligoPhore is the targeted delivery to inflamed tissues, making it
particularly well suited for the treatment of arthritis with
oligonucleotides, both in terms of efficacy and safety.
"Osteoarthritis can have a significantly detrimental impact on
the well-being and quality of life of patients, often over many
years or even decades, yet there is still no disease-modifying
treatment available,” Dr. Wickline added. “While our AM-411 program
is targeting rheumatoid arthritis, we envision extending its
potential use to osteoarthritis as well."
Earlier this week, the Company announced the initiation of
AM-411, a development program based on its proprietary OligoPhore
delivery platform and siRNA targeting NF-κB, for a novel generation
of rheumatoid arthritis (RA) therapeutics.
Osteoarthritis to become one of the most prevalent diseases
in the coming decades
Osteoarthritis is a degenerative joint disease that can affect
the many tissues of the joint.1 It can degrade cartilage, change
bone shape and cause inflammation, resulting in pain, stiffness and
loss of mobility. OA can affect any joint, but typically affects
hands, knees, hips, lower back and neck. Its signs and symptoms
typically show up more often in individuals over age 50, but OA can
affect much younger people, too, especially those who have had a
prior joint injury. There is no cure for OA, but there are ways to
manage OA to minimize pain, continue physical activities, maintain
a good quality of life and remain mobile.
OA is by far the most common form of arthritis, affecting more
than 32.5 million adults in the United States, according to the
Centers for Disease Control and Prevention. The global prevalence
of OA is increasing and the burden of the disease will rise.2 The
medical cost of osteoarthritis in various high-income countries has
been estimated to account for between 1% and 2.5% of the gross
domestic product of these countries, with hip and knee joint
replacements representing the major proportion of these health-care
costs.
About International Journal of Oral Science
The International Journal of Oral Science seeks to publish all
aspects of oral science and interdisciplinary fields, including
basic, applied and clinical research. The Journal publishes
peer-reviewed articles that describe new research results and
review articles that provide succinct summaries of an area in oral
science. The International Journal of Oral Science is published by
Springer Nature. For more information,
visit: https://www.nature.com/ijos/aims
About OligoPhore
OligoPhore is a versatile platform for safe and effective
delivery of oligonucleotides such as siRNA (small interfering
ribonucleic acid) into target cells. It is based on a proprietary
21-amino acid peptide that can engage any type of RNA in rapid
self-assembly into a polyplex. The polyplex has a size, charge, and
other physical features that allow it to escape hepatic clearance
and thus to reach other target tissues than the liver. OligoPhore
protects the RNA payload from degradation in the circulation and
allows for rapid cellular uptake, while enabling pH-dependent
nucleotide endosomal escape and cytoplasmic delivery. Effective
delivery and positive treatment outcomes have been demonstrated in
more than 10 murine models of disease for targets in the NF-κB
family, various members of the ETS transcription factor family, and
targets in the JNK and TAM pathways.
About Altamira Therapeutics
Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing
therapeutics that address important unmet medical needs. The
Company is currently active in three areas: the development of RNA
therapeutics for extrahepatic therapeutic targets (OligoPhore™ /
SemaPhore™ platforms; preclinical), nasal sprays for protection
against airborne allergens and, where approved, viruses (Bentrio™;
commercial) or for the treatment of vertigo (AM-125; Phase 2), and
the development of therapeutics for intratympanic treatment of
tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded
in 2003, it is headquartered in Hamilton, Bermuda, with its main
operations in Basel, Switzerland. For more information,
visit: https://altamiratherapeutics.com/
Forward-Looking Statements
This press release may contain statements that constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements are statements
other than historical facts and may include statements that address
future operating, financial or business performance or Altamira
Therapeutics' strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as "may",
"might", "will", "should", "expects", "plans", "anticipates",
"believes", "estimates", "predicts", "projects", "potential",
"outlook" or "continue", or the negative of these terms or other
comparable terminology. Forward-looking statements are based on
management's current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include, but are not limited to, the approval and
timing of commercialization of AM-301, Altamira Therapeutics' need
for and ability to raise substantial additional funding to continue
the development of its product candidates, the timing and conduct
of clinical trials of Altamira Therapeutics' product candidates,
the clinical utility of Altamira Therapeutics' product candidates,
the timing or likelihood of regulatory filings and approvals,
Altamira Therapeutics' intellectual property position and Altamira
Therapeutics' financial position, including the impact of any
future acquisitions, dispositions, partnerships, license
transactions or changes to Altamira Therapeutics' capital
structure, including future securities offerings. These risks and
uncertainties also include, but are not limited to, those described
under the caption "Risk Factors" in Altamira Therapeutics' Annual
Report on Form 20-F for the year ended December 31, 2021, and in
Altamira Therapeutics' other filings with the SEC, which are
available free of charge on the Securities Exchange Commission's
website at: www.sec.gov. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those indicated.
All forward-looking statements and all subsequent written and oral
forward-looking statements attributable to Altamira Therapeutics or
to persons acting on behalf of Altamira Therapeutics are expressly
qualified in their entirety by reference to these risks and
uncertainties. You should not place undue reliance on
forward-looking statements. Forward-looking statements speak only
as of the date they are made, and Altamira Therapeutics does not
undertake any obligation to update them in light of new
information, future developments or otherwise, except as may be
required under applicable law.
CONTACT Investors@altamiratherapeutics.com
800-460-0183
1 https://www.arthritis.org/diseases/osteoarthritis
2 Hunter DJ & Bierma-Zeinstra S (2019), Osteoarthritis,
Lancet 393:1745-59.
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
